Gilead tack­les a big PhI­II pro­gram for block­buster hope­ful fil­go­tinib

Gilead $GILD has em­barked on an am­bi­tious Phase III pro­gram for fil­go­tinib, one of the most close­ly-watched drugs now in the late-stage pipeline for rheuma­toid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.